SeaStar Medical (ICU) estimates a U.S. total addressable market for its proprietary, patented Selective Cytopheretic Device in five clinical indications, subject to U.S. FDA approvals, of $25B-$33B.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU:
- SeaStar Medical announces activation of Sentara Norfolk General as active site
- SeaStar announces two advisory firms recommended vote favor of proposals
- SeaStar Medical reaches milestone of 100th QUELIMMUNE commercial device
- Seastar Medical Faces Distribution Challenges with Self-Marketing of QUELIMMUNE
- ICU Earnings Report this Week: Is It a Buy, Ahead of Earnings?